The University of Chicago Header Logo

Connection

Neil Sengupta to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Neil Sengupta has written about Antibodies, Monoclonal, Humanized.
Neil Sengupta
Connection Strength
0.474
Antibodies, Monoclonal, Humanized
  1. Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scand J Gastroenterol. 2020 Jul; 55(7):800-805.
    View in: PubMed
    Score: 0.474
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.